# Phase I Study to Evaluate a Human Monoclonal Antibody (MAb) 10E8VLS Administered Alone or Concurrently With MAb VRC07-523LS Via Subcutaneous Injection in Healthy Adults

> **NCT03565315** · PHASE1 · TERMINATED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 9 (actual)

## Conditions studied

- Healthy Adult Immune Response

## Interventions

- **BIOLOGICAL:** VRC-HIVMAB095-00-AB (10E8VLS)
- **BIOLOGICAL:** VRC-HIVMAB075-00-AB (VRC07-523LS)

## Key facts

- **NCT ID:** NCT03565315
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-10
- **Primary completion:** 2019-03-04
- **Final completion:** 2019-03-04
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Sponsor/PI voluntarily paused and stopped study after observing several Grade 2 and Grade 3 redness local reactogenicity reactions at 10E8VLS injection sites
- **Last updated:** 2020-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03565315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03565315, "Phase I Study to Evaluate a Human Monoclonal Antibody (MAb) 10E8VLS Administered Alone or Concurrently With MAb VRC07-523LS Via Subcutaneous Injection in Healthy Adults". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03565315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*